Skip to search formSkip to main contentSkip to account menu

SB 1518

Known as: SB-1518, SB1518 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Background Pacritinib (SB1518) is a novel oral JAK2-FLT3 inhibitor. To date, once-daily (QD) dosing of pacritinib has been… 
2012
2012
Abstract The BCR-ABL-negative myeloproliferative neoplasms (MPNs) include essential thrombocythemia, polycythemia vera, and… 
2012
2012
Herein, we describe the synthesis and SAR of a series of small molecule macrocycles that selectively inhibit JAK2 kinase within… 
2011
2011
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Introduction: Janus kinase 2 (JAK2) and fms-related… 
2011
2011
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Introduction: Here we present the unique chemical… 
2010
2010
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Introduction FLT3 and JAK2 are tyrosine kinases… 
Review
2010
Review
2010
Recent FDA action (through, October 2010) related to Qnexa, Linjeta, JZP-6, Bydureon, Zalbin, Staccato loxapine, Tapentadol… 
2009
2009
Abstract 1888 Poster Board I-911 Introduction: Abnormalities in JAK2 and FLT3 kinases are reported in various hematological… 
2009
2009
Abstract 2913 Poster Board II-889 Introduction: Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) in which the… 
2007
2007
JAK2 is the most common mutated gene in bcr-abl-negative chronic myeloproliferative disorders (MPDs) making it an attractive…